BLAKE BOND: Open Payments
NPI 1730878174 · LEXINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$574 in 32 payments from 14 companies in 2025. Trend: 2023 $115 · 2024 $226 · 2025 $574
Food & beverage: $574
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $145 |
| Novo Nordisk Inc | 6 | $109 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| AstraZeneca Pharmaceuticals LP | 3 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| PFIZER INC. | 2 | $37 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Exact Sciences Corporation | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Merck Sharp & Dohme LLC | 1 | $16 |
Products named: VRAYLAR, REXULTI, Ozempic, Wegovy, QULIPTA, CAPLYTA, PREVNAR 20, SHINGRIX.
Industry payments across NC — which companies pay providers there.
